These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1926674)

  • 21. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of trospium chloride on the lower urinary tract function].
    Suzuki T; Nishizawa O; Sugaya K; Kohama T; Matsuzaki A; Fukuda T; Tsukada T; Harada T; Tsuchida S
    Hinyokika Kiyo; 1990 Sep; 36(9):1047-51. PubMed ID: 2239610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life].
    Fuertes ME; García Matres MJ; González Romojaro V; de la Rosa S; Anguera Vila A; de la Peña J; Leiva Galvis O; Sánchez Chapado M
    Arch Esp Urol; 2000 Mar; 53(2):125-36. PubMed ID: 10802918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study.
    Walter P; Grosse J; Bihr AM; Kramer G; Schulz HU; Schwantes U; Stöhrer M
    Neurourol Urodyn; 1999; 18(5):447-53. PubMed ID: 10494116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida.
    Xiao CG; Du MX; Li B; Liu Z; Chen M; Chen ZH; Cheng P; Xue XN; Shapiro E; Lepor H
    J Urol; 2005 Jun; 173(6):2112-6. PubMed ID: 15879861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trospium chloride for the treatment of detrusor instability in children.
    Lopez Pereira P; Miguelez C; Caffarati J; Estornell F; Anguera A
    J Urol; 2003 Nov; 170(5):1978-81. PubMed ID: 14532838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined antimuscarinics for treatment of neurogenic overactive bladder.
    Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
    Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.
    Madersbacher H; Stöhrer M; Richter R; Burgdörfer H; Hachen HJ; Mürtz G
    Br J Urol; 1995 Apr; 75(4):452-6. PubMed ID: 7788255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
    O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
    J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neurogenic urinary incontinence: current treatment concepts].
    Madersbacher H
    Urologe A; 1990 Jul; 29(4):176-84. PubMed ID: 2205038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial.
    Cardozo L; Chapple CR; Toozs-Hobson P; Grosse-Freese M; Bulitta M; Lehmacher W; Strösser W; Ballering-Brühl B; Schäfer M
    BJU Int; 2000 Apr; 85(6):659-64. PubMed ID: 10759661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle].
    Wehnert J; Sage S
    Z Urol Nephrol; 1989 May; 82(5):259-63. PubMed ID: 2665385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J; Göcking K; Bersch U
    BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.